These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19076089)

  • 1. [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
    Belousov IuB; Shestakova MV; Belousov DIu
    Kardiologiia; 2008; 48(12):14-9. PubMed ID: 19076089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
    Frei A; Palmer AJ; Burnier M; Hess B
    Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria.
    Smith DG; Nguyen AB; Peak CN; Frech FH
    J Manag Care Pharm; 2004; 10(1):26-32. PubMed ID: 14720103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F;
    Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.
    Annemans L; Demarteau N; Hu S; Lee TJ; Morad Z; Supaporn T; Yang WC; Palmer AJ
    Value Health; 2008; 11(3):354-64. PubMed ID: 17888064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
    Rodby RA; Chiou CF; Borenstein J; Smitten A; Sengupta N; Palmer AJ; Roze S; Annemans L; Simon TA; Chen RS; Lewis EJ;
    Clin Ther; 2003 Jul; 25(7):2102-19. PubMed ID: 12946554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
    Maniadakis N; Ekman M; Fragoulakis V; Papagiannopoulou V; Yfantopoulos J
    Eur J Health Econ; 2011 Jun; 12(3):253-61. PubMed ID: 20411401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Belsey JD
    Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
    Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Schute LL
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
    Gialama F; Maniadakis N
    Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.